An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Revance Therapeutics, Inc. (RVNC) will release its third quarter 2023 financial results on November 8, 2023, after the market closes. A conference call and live webcast will be held on the same day at 4:30 p.m. ET to discuss the results and provide a corporate update. Interested individuals can dial (833) 470-1428 to listen to the conference call or access the webcast link on the company's website. A webcast replay will be available until February 8, 2024.
Positive
None.
Negative
None.
Conference Call Scheduled for Wednesday, November 8, 2023 at 4:30 p.m. ET
NASHVILLE, Tenn.--(BUSINESS WIRE)--
Revance Therapeutics, Inc. (RVNC) today announced that the company will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results and provide a corporate update.
Individuals interested in listening to the conference call may do so by dialing (833) 470-1428 for U.S. and Canadian callers, and reference conference ID 509643 or from the webcast link in the investor relations section of the company's website at: www.revance.com.
A webcast replay will be available beginning November 8, 2023, at 4.30 p.m. PT / 7.30 p.m. ET to February 8, 2024 at 4.30 p.m. PT / 7.30 p.m. ET. To access the replay, please register via the webcast link on the events page. The webcast will be available in the investor relations section on the company's website for 90 days following the completion of the call.
About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY® in China.
“Revance” and the Revance logo, and DAXXIFY® are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA. BOTOX® is a registered trademark of Allergan, Inc.
Media
Revance Therapeutics, Inc.:
Sara J. Fahy, 949-887-4476
sfahy@revance.com
Source: Revance Therapeutics, Inc.
FAQ
When will Revance Therapeutics release its third quarter 2023 financial results?
Revance Therapeutics will release its third quarter 2023 financial results on November 8, 2023, after the market closes.
What time is the conference call and live webcast scheduled?
The conference call and live webcast are scheduled for 4:30 p.m. ET on November 8, 2023.
How can I listen to the conference call?
To listen to the conference call, you can dial (833) 470-1428 if you are in the U.S. or Canada. The conference ID is 509643. Alternatively, you can access the webcast link on the investor relations section of Revance Therapeutics' website.
How long will the webcast replay be available?
The webcast replay will be available from November 8, 2023, at 4:30 p.m. PT / 7:30 p.m. ET until February 8, 2024, at 4:30 p.m. PT / 7:30 p.m. ET.
